Taltz

TALTZ^® is a humanized interleukin-17A antagonist indicated for the treatment of:

• patients aged 6 years or older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. (
  1.1 Plaque Psoriasis

  TALTZ^®is indicated for the treatment of patients 6 years of age and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
  )
• adults with active psoriatic arthritis. (
  1.2 Psoriatic Arthritis

  TALTZ is indicated for the treatment of adult patients with active psoriatic arthritis.
  )
• adults with active ankylosing spondylitis. (
  1.3 Ankylosing Spondylitis

  TALTZ is indicated for the treatment of adult patients with active ankylosing spondylitis.
  )
• adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation. (
  1.4 Non-radiographic Axial Spondyloarthritis

  TALTZ is indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation.
  )